Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Coordinated expansion of CD163⁺ monocytes and immature CD177⁺ neutrophils marks severe neurotoxicity after CD19 CAR T cell therapy.
Journal: bioRxiv : the preprint server for biology
Published: July 17, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.
Journal: JCO clinical cancer informatics
Published: January 14, 2026
Fear of Cancer Recurrence in Hematopoietic Cell Transplantation Survivors.
Journal: Transplantation and cellular therapy
Published: January 14, 2026
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.
Journal: Haematologica
Published: December 19, 2025
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.
Journal: Blood cancer journal
Published: November 04, 2025
A Practical Guide to Competing Risk Analysis for Transplant and Cell Therapy Research.
Journal: Transplantation and cellular therapy
Published: July 10, 2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials.
Journal: Transplantation and cellular therapy
Published: May 18, 2025
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy.
Journal: Transplantation and cellular therapy
Published: April 28, 2025
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma.
Journal: Haematologica
Published: April 07, 2025
Last Updated: 09/26/2026